Termination of Ultragenyx’s UX053 Phase I/II study is a minor setback for mRNA therapeutics:…
UX053 was one of five non-vaccine mRNA therapeutics in clinical trial development. The other four are all currently in Phase I/II…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
mRNA therapeutics
Moderna’s non-vaccine mRNA therapeutic can generate $278 million in 2028 if approved: GlobalData
mRNA-3927 targets a rare genetic disorder, propionic acidemia, in which patients are unable to process certain parts of proteins…
Merck acquires Germany-based CDMO, AmpTec
The acquisition to expand Merck’s lipid manufacturing expertise and mRNA capabilities for vaccines, treatments and diagnostics